Arginine vasopressin as a rescue vasopressor agent in the operating room

Current Opinion in Anaesthesiology

Volumn 18, Issue 4, 2005, Pages 396-404

  Jochberger, Stefan ^a   Wenzel, Volker ^a   Dünser, Martin W ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Arginine vasopressin; Cardiopulmonary resuscitation; Haemorrhagic shock; Operating room; Vasodilatory shock

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANESTHETIC AGENT; ARGIPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; HYPERTENSIVE AGENT; LACTIC ACID; LEVOTHYROXINE; LIOTHYRONINE; METHYLPREDNISOLONE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PHENYLEPHRINE; SOMATOSTATIN; TERLIPRESSIN;

ANAPHYLACTIC SHOCK; BRAIN DEATH; BRAIN INJURY; BRAIN VASOSPASM; CARCINOID; CARCINOID SYNDROME; CARDIOGENIC SHOCK; CHRONIC DISEASE; CIRCULATION; CLINICAL TRIAL; DRUG EFFICACY; ELECTROCARDIOGRAPHY; EPIDURAL ANESTHESIA; GASTROINTESTINAL DISEASE; HEART ARREST; HEART HEMODYNAMICS; HEART OUTPUT; HEART RHYTHM; HEART SURGERY; HEMORRHAGIC SHOCK; HORMONE SUBSTITUTION; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; ISCHEMIA; LACTIC ACIDOSIS; LIVER DISEASE; LIVER PERFUSION; META ANALYSIS; NONHUMAN; OPERATING ROOM; ORGAN DONOR; PERIOPERATIVE PERIOD; PHEOCHROMOCYTOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SPINAL ANESTHESIA; SPLANCHNIC BLOOD FLOW; SUBARACHNOID HEMORRHAGE; SWINE; TACHYCARDIA; VASODILATATION;

EID: 23044465640     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000174963.35877.81     Document Type: Review

References (89)

1. Oliver H, Schafer E. On the physiological action of extracts of the pituitary body and certain other glandular organs. J Physiol 1895; 18:277-279.
2. Howell W. The physiological effects of the hypophysis cerebri and infundibular body. J Exp Med 1898; 3:245-258.
3. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intens Care Med 2004; 30:1276-1291. The authors give a detailed overview on the physiological characteristics of AVP as well as on the use of AVP in patients with septic shock.
4. Kleemann PP, Jantzen JP, Dick W. Undesirable effects following the local injection of ornipressin during general anesthesia: can the risk be lessened? A prospective study. Anaesthesist 1988; 37:551 -557.
5. Lindner KH, Strohmenger HU, Ensinger H, et al. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology 1992; 77:662-668.
6. Lindner KH, Brinkmann A, Pfenninger EG, et al. Effect of vasopressin on hemodynamic variables, organ blood flow, and acid-base status in a pig model of cardiopulmonary resuscitation. Anesth Analg 1993; 77:427-435.
7. Lindner KH, Prengel AW, Pfenninger EG, et al. Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation 1995; 91:215-221.
8. Prengel AW, Lindner KH, Keller A. Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke 1996; 27:1241-1248.
9. Wenzel V, Lindner KH, Prengel AW, et al. Endobronchial vasopressin improves survival during cardiopulmonary resuscitation in pigs. Anesthesiology 1997; 86:1375-1381.
10. Wenzel V, Lindner KH, Augenstein S, et al. Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Crit Care Med 1999; 27:1565-1569.
11. Prengel AW, Lindner KH, Wenzel V, et al. Splanchnic and renal blood flow after cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Resuscitation 1998; 38:19-24.
12. Wenzel V, Lindner KH, Krismer AC, et al. Survival with full neurologic recovery and no cerebral pathology after prolonged cardiopulmonary resuscitation with vasopressin in pigs. J Am Coll Cardiol 2000; 35:527-533.
13. Lindner KH, Prengel AW, Brinkmann A, et al. Vasopressin administration in refractory cardiac arrest. Ann Intern Med 1996; 124:1061-1064.
14. Morris DC, Dereczyk BE, Brzybowski M, et al. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med 1997; 4:878-883.
15. Lindner KH, Dirks B, Strohmenger HU, et al. A randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349:535-537.
16. Li PF, Chen TT, Zhang JM, et al. Clinical study on administration of vasopressin during closed-chest cardiopulmonary resuscitation. Chin Crit Care Med 1999; 11:28-31.
17. Stiell IG, Hebert PC, Wells GA, et al. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomized uncontrolled trial. Lancet 2001; 358:105-109.
18. Wenzel V, Krismer AC, Arntz HR, et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004; 350:105-113. This is the largest prospective, randomized, controlled, multicentre trial on the use of AVP in out-of-hospital cardiac arrest. The effects of vasopressin were similar to those of epinephrine in the management of ventricular fibrillation and pulseless electrical activity, but vasopressin was superior to epinephrine in patients with asystole. Vasopressin followed by epinephrine may be more effective than epinephrine alone in the treatment of refractory cardiac arrest.
19. Aung KK, Htay T. Vasopressin for cardiac arrest. A systematic review and meta-analysis. Arch Intern Med 2005; 165:17-24. This is the first meta-analysis on the use of AVP in cardiac arrest. The authors conclude that there is no clear advantage of vasopressin over epinephrine in the treatment of cardiac arrest.
20. Guidelines for 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. International consensus on science. Circulation 2000; 102 (Suppl.):I1-I384.
21. Guidelines for 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. International consensus on science. Resuscitation 2000; 46:1-447.
22. Krismer AC, Wenzel V, Stadibauer KH, et al. Vasopressin during cardiopulmonary resuscitation: a progress report. Crit Care Med 2004; 32(Suppl.): S432-S435.
23. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25:1279-1282.
24. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125.
25. Malay MB, Ashton RC Jr, Landry DW, et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47:699-703.
26. Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intens Care Med 2001; 27:1416-1421.
27. Dünser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001; 93:7-13.
28. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487-493.
29. Patel BM, Chittock DR, Russel JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576-582.
30. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359:1209-1210.
31. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313-2319.
32. Klinzing S, Simon M, Reinhart K, et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31: 2646-2650.
33. Van Haren FM, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003; 124:2256-2260.
34. Obritsch MD, Jung R, Fish DN, et al. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 2004; 38:1117-1122.
35. Hall LG, Oyen LJ, Taner CB, et al. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy 2004; 24:1002-1012.
36. Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, et al. Terlipressin for catecholamine-resistant septic shock in children. Intens Care Med 2004; 30:477-480.
37. Albert M, Losser MR, Hayon D, et al. Systemic and renal macro- and microcirculatory responses to arginine vasopressin in endotoxic rabbits. Crit Care Med 2004; 32:1891-1898. In this prospective, randomized, controlled animal study, AVP preserved renal blood flow, in particular to the cortex, during endotoxemia.
38. Guzman JA, Rosado AE, Kruse JA. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 2003; 95:803-809.
39. Dünser MW, Hasibeder WR, Wenzel V, et al. Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 2004; 32:1266-1271. In this prospective study, AVP was found to increase prolactin plasma concentrations significantly. There were no changes in the plasma levels of other hormones such as adrenocorticotrophic hormone or cortisol during continuous AVP infusion. The haemodynamic response to AVP infusion was independent of vasopressin plasma concentrations at baseline.
40. Westphal M, Freise H, Kehrel BE, et al. Arginine vasopressin compromises gut mucosal microcirculation in septic rats. Crit Care Med 2004; 32:194-200. In this animal experiment, the authors observed severe abnormalities in gut mucosal blood flow after AVP infusion in septic rats, accompanied by an augmented inflammatory response to the septic injury. The effects of AVP on microvascular blood flow in this model may have been related to AVP activities on larger arterioles (> 40 μm), a concomitant reduction in cardiac output, or both.
41. Martikainen TJ, Tenhunen JJ, Uusaro A, et al. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 2003; 97:1756-1763.
42. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional hemodynamics in catecholamine-treated hyperkinetic septic shock. Intens Care Med 2004; 30:597-604. In this prospective, open label study, 15 patients with norepinephrine-resistant septic shock were included. Terlipressin significantly increased gastric mucosal perfusion, urine output and creatinine clearance by an increase in the mean arterial pressure.
43. Dünser MW, Fries DR, Schobersberger W, et al. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth Analg 2004; 99:201-206.
44. Dubois MJ, De Backer D, Creteur J, et al. Effect of vasopressin on sublingual microcirulation in a patient with distributive shock. Intens Care Med 2003; 29:1020-1023.
45. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873. In 2003, critical care and infectious disease experts representing 11 international organizations developed management guidelines for severe sepsis and septic shock that would be of practical use for the bedside clinician, under the auspices of the Surviving Sepsis Campaign, an international effort to increase awareness and improve outcome in severe sepsis.
46. Voelckel W, Wenzel V. Managing hemorrhagic shock: fluids on the way out - drugs on the way in? Crit Care Med 2003; 31:2552-2553.
47. Ericsson BF. Hemodynamic effects of vasopressin. An experimental study in normovolemic and hypovolemic anesthetized dogs. Acta Chir Scand Suppl 1971; 414:1-29.
48. Morales D, Madigan J, Cullinane S, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999; 100:226-229.
49. Raedler C, Voelckel WG, Wenzel V, et al. Treatment of uncontrolled hemorrhagic shock after liver trauma: fatal effects of fluid resuscitation versus improved outcome after vasopressin. Anesth Analg 2004; 98:1759-1766. In this animal model of severe liver trauma with uncontrolled haemorrhagic shock, vasopressin, but not saline placebo or fluid resuscitation, improved short-term survival. Arterial blood pressure 5 min after the intervention was significantly higher after vasopressin than with saline placebo or fluid resuscitation. Vasopressin improved abdominal organ blood flow but did not cause further blood loss. Seven out of seven vasopressin pigs survived until bleeding was controlled and 60 min thereafter, whereas seven out of seven saline placebo and seven out of seven fluid resuscitation pigs died.
50. Voelckel WG, Raedler C, Wenzel V, et al. Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Crit Care Med 2003; 31:1160-1165.
51. Stadlbauer KH, Wagner-Berger HG, Raedler C, et al. Vasopressin, but not fluid resuscitation, enhances survival in a liver trauma model with uncontrolled and otherwise lethal hemorrhagic shock in pigs. Anesthesiology 2003; 98:699-704.
52. Krismer AC, Wenzel V, Voelckel WG, et al. Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock: Three cases and a brief analysis of the literature. Anaesthesist 2004; 1 7. e-pub ahead of print. This is the first report on the clinical use of AVP in three patients with uncontrolled haemorrhage.
53. Haas T, Voelckel WG, Wiedermann F, et al. Successful resuscitation of a traumatic cardiac arrest victim in hemorrhagic shock with vasorpess: a case report brief review of the literature. J Trauma 2004; 57:177-179.
54. Williams SR, Denault AY, Pellerin M, et al. Vasopressin for treatment of shock following aprotinin administration. Can J Anesth 2004; 51:169-172.
55. Schummer W, Schummer C, Wippermann J, et al. Anaphylactic shock: is vasopressin the drug of choice? Anesthesiology 2004; 101:1025-1027.
56. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Int Arch Allergy Immunol 2004; 134:260-261.
57. Tsuda A, Tanaka KA, Huraux C, et al. The in vitro reversal of histamine-induced vasodilation in the human internal mammary artery. Anesth Analg 2001; 93:1453-1459.
58. Peters J, Schlaghecke R, Thouet H, et al. Endogenous vasopressin supports blood pressure and prevents severe hypotension during epidural anesthesia in conscious dogs. Anesthesiology 1990; 73:694-702.
59. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbrid LE, editors. Goodman and Gilman's Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill; 1996. 721.
60. De Kock M, Laterre PF, Andruetto P, et al. Ornipressin (Por 8): an efficient alternative to counteract hypotension during combined general/epidural anesthesia. Anesth Analg 2000; 90:1301-1307.
61. Braun EB, Palin CA, Hogue CW. Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenol. Anesth Analg 2004; 99:36-37.
62. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 116:973-980.
63. Chernow B, Roth BL. Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ Shock 1986; 18:141-155.
64. Albright TN, Zimmermann MA, Selzman CH. Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care Med 2002; 11:326-332.
65. Argenziano M, Chen JM, Cullinane S, et al. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 1999; 18:814-817.
66. Argenziano M, Choudhri AF, Oz MC, et al. A prospective, randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96(Suppl. II):II286-II290.
67. Dünser MW, Mayr AJ, Stallinger A, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intens Care Med 2002; 28:746-751.
68. Gold JA, Cullinane S, Chen J, et al. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med 2000; 28:249-252.
69. Suzuki Y, Satoh S, Oyama H, et al. Vasopressin mediated vasodilation of cerebral arteries. J Auton Nerv Syst 1994; 49(Suppl.):S129-S132.
70. Yeh CC, Wu CT, Lu CH, et al. Early use of small-dose vasopressin for unstable hemodynamics in an acute brain injury pateint refractory to catecholamine treatment: a case report. Anesth Analg 2003; 97:577-579.
71. Bradley PG, Allen EK, Menon DK. Terlipressin for cerebral perfusion pressure support in a patient with septic shock. Anaesthesia 2004; 59:619-620.
72. Muehlschlegel S, Gabrielli A, Wenzel V, et al. Hypervolemic, hypertensive, hyperdynamic therapy in subarachnoid hemorrhage with arginine vasopressin. Presented at the 57th Annual Meeting of the American Academy of Neurology. Miami, FL, USA, 9-16 April 2004 [Abstract 651122].
73. Yoshioka T, Sugimoto H, Uenishi M, et al. Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosugery 1986; 18:565-567.
74. Iwai A, Sakano T, Uenishi M, et al. Effects of vasopressin and catecholamines on the maintenance of circulatory stability in brain-dead patients. Transplantation 1989; 48:613-617.
75. Chen JM, Cullinane S, Spanier TB, et al. Vasopressin deficiency and presser hypersensitivity in hemodynamically unstable organ donors. Circulation 1999; 100:11244-11246.
76. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003; 75:482-487.
77. Barbant SM, Bertrand M, Eyraud D, et al. The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists. Anesth Analg 1999; 89:1388-1392.
78. Freedman M, Kundig H, Leiman BC. The treatment of resistant hypotension with ornipressin. A case report. S Afr J Med 1985; 67:29-31.
79. Eyraud D, Barbant S, Dieudonne N, et al. Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Anesth Analg 1999; 88:980-984.
80. Meersschaert K, Brun L, Gourdin M, et al. Terlipressin-ephedrine versus ephedrine to treat hypotension at the induction of anesthesia in patients chronically treated with angiotensin converting-enzyme inhibitors: a prospective, randomized, double-blinded, crossover study. Anesth Analg 2002; 49:835-840.
81. Boccara G, Quattara A, Godet G, et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology 2003; 98:1338-1344.
82. Morelli A, Tritapepe L, Rocco M, et al. Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: effects on systemic and regional hemodynamics. Anesthesiology 2005; 102:12-19. This study showed the efficacy of terlipressin in the treatment of hypotension episodes in anaesthetized patients chronically treated with renin-angiotensin system inhibitors, angiotensin converting-enzyme inhibitors, and angiotensin II receptor antagonists. However, the negative effects on gastric mucosal perfusion and the risk of iatrogenic oxygen supply dependency of terlipressin need to be taken into account.
83. Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003; 75:926-930.
84. Tan SG, Koay CK, Chan ST. The use of vasopressin to treat catecholamine-resistant hypotension after pheochromocytoma removal. Anaesth Intens Care 2002; 30:477-480.
85. Augoustides JG, Abrams M, Berkowitz D, et al. Vasopressin for hemodynamic rescue in catecholamine-resistant vasoplegic shock after resection of massive pheochromocytoma. Anesthesiology 2004; 101:1022-1024.
86. Zimmer C, Günnicker M, Peters J. Anaesthetic management for hemihepatectomy in a patient with carcinoid syndrome. AINS 2001; 36:763-767.
87. Parris W, Oates J, Kambam J, et al. Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome. Can J Anesth 1988; 35:413-416.
88. Hughes EW, Hodkinson BP. Carcinoid syndrome: the combined use of ketanserin and octreotide in the management of an acute crisis during anaesthesia. Anaesth Intens Care 1989; 17:367-370.
89. Veall GRQ, Peacock JE, Bax NDS, et al. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994; 72:335-341.